Collegium Pharmaceutical Inc COLL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if COLL is a good fit for your portfolio.
News
-
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
-
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
-
Thinking about buying stock in BigBear.ai, Supernus Pharmaceuticals, Collegium Pharmaceutical, Duolingo, or Cryptoblox Technologies?
-
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
-
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Trading Information
- Previous Close Price
- $34.74
- Day Range
- $34.92–36.51
- 52-Week Range
- $20.83–40.95
- Bid/Ask
- $35.93 / $35.94
- Market Cap
- $1.18 Bil
- Volume/Avg
- 618,659 / 427,229
Key Statistics
- Price/Earnings (Normalized)
- 6.47
- Price/Sales
- 2.56
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 6.60%
Company Profile
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 197
- Website
- https://www.collegiumpharma.com
Comparables
Valuation
|
Metric
|
COLL
|
SCLX
|
EGRX
|
|---|---|---|---|
Price/Earnings (Normalized) | 6.47 | — | 0.98 |
Price/Book Value | 5.66 | — | 0.24 |
Price/Sales | 2.56 | 2.65 | 0.23 |
Price/Cash Flow | 5.74 | — | 1.24 |
Price/Earnings
COLL
SCLX
EGRX
Financial Strength
|
Metric
|
COLL
|
SCLX
|
EGRX
|
|---|---|---|---|
Quick Ratio | 1.07 | 0.15 | 1.52 |
Current Ratio | 1.17 | 0.19 | 2.16 |
Interest Coverage | 1.72 | −106.04 | 5.39 |
Quick Ratio
COLL
SCLX
EGRX
Profitability
|
Metric
|
COLL
|
SCLX
|
EGRX
|
|---|---|---|---|
Return on Assets (Normalized) | 18.85% | −106.47% | 6.32% |
Return on Equity (Normalized) | 117.55% | — | 10.51% |
Return on Invested Capital (Normalized) | 28.83% | −1,960.39% | 9.73% |
Return on Assets
COLL
SCLX
EGRX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Qhdyhbxtp | Mpw | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Blzgtpscd | Ljtwk | $68.4 Bil | |
HLN
| Haleon PLC ADR | Pcgrfwnj | Jyyz | $37.0 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Dsnrrmz | Tqyc | $14.5 Bil | |
VTRS
| Viatris Inc | Csmhcpzx | Qcjn | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Ffjbnmgl | Dmck | $12.0 Bil | |
CTLT
| Catalent Inc | Rxvwjjvl | Zzpxx | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Fblwdzzf | Qgqx | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Jnlvgqrd | Gmx | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Ggrlyyfn | Rwcsnw | $3.5 Bil |